Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 47Brain Neoplasms 24Central Nervous System Neoplasms 22Astrocytoma 16Glioma 15Medulloblastoma 11Neoplasms 8Oligodendroglioma 7Lymphoma 7Recurrence 6Gliosarcoma 6Spinal Cord Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, AIDS-Related 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Ependymoma 2Burkitt Lymphoma 2Uveal Melanoma 1Solid Tumor 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Newly Diagnosed High Grade Glioma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1

Interventions

Transcranial Direct Current Stimulation 1Palliative Care 1Modafinil 1Methods 1Mental Status and Dementia Tests 1Magnetic Resonance Spectroscopy 1Lovastatin 1Lomustine 1Lamotrigine 1Functional Status 1Exercise 1Donepezil 1DNA Methylation 1Cognitive Training 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cognition Disorders × Lomustine × Clear all
NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
592 enrolled
CNS

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡